Crescent Biopharma to Present at November Investor Conferences
Crescent Biopharma (CBIO) management is scheduled to present at investor conferences on November 9, 10 and 18, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Crescent Biopharma (CBIO) management is scheduled to present at investor conferences on November 9, 10 and 18, 2026.
Fireside chats are scheduled at Guggenheim in Boston at 8:30 a.m. ET, Stifel in New York at 1:20 p.m. ET, and Jefferies in London at 3:00 p.m. GMT/10:00 a.m. ET, respectively. Each presentation will be webcast through the company’s investor website, with replays available for 90 days.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November:
- Guggenheim 3rd Annual Healthcare Innovation Conference, fireside chat on Monday, November 9, 2026 at 8:30 a.m. ET in Boston.
- Stifel 2026 Healthcare Conference, fireside chat on Tuesday, November 10, 2026 at 1:20 p.m. ET in New York.
- Jefferies Global Healthcare Conference, fireside chat on Wednesday, November 18, 2026 at 3:00 p.m. GMT/10:00 a.m. ET in London.
A live webcast of each presentation will be available in the Investors section of the Company's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contacts
Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019
